Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
Summary
- Eligibility
- for people ages 18-65 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Tenaya Therapeutics
- ID
- NCT05836259
- Phase
- Phase 1 Cardiomyopathy Research Study
- Study Type
- Interventional
- Participants
- Expecting 15 study participants
- Last Updated